证券代码：300981 证券简称：中红医疗 公告编号：2025-108 中红普林医疗用品股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、担保情况概述 中红普林医疗用品股份有限公司（以下简称"公司"）分别于 2024 年 12 月 9 日、2024 年 12 月 25 日召开第四届董事会第四次会议、2024 年第三次临时 股东大会，审议通过了《关于公司及子公司 2025 年度向银行申请综合授信额度 暨公司为子公司申请综合授信额度提供担保的议案》，同意公司为控股子公司 2025 年度向金融机构申请的授信额度提供担保，其中，为资产负债率 70%（含） 以上的控股子公司提供担保额度为不超过 15 亿元，为资产负债率低于 70%的控 股子公司提供担保额度为不超过 10 亿元，担保额度总计不超过 25 亿元。具体内 容详见《关于公司及子公司 2025 年度向银行申请综合授信额度暨公司为子公司 申请综合授信额度提供担保的公告》（公告编号：2024-083）。 二、担保进展情况 近日，为满足公司全资子公司北京林普医疗用品有限公 ...

来源：新浪证券-红岸工作室 12月18日，中红医疗涨0.46%，成交额6745.59万元，换手率1.31%，总市值56.10亿元。 异动分析 核污染防治+宠物经济+医疗器械概念+人民币贬值受益+国企改革 1、2024年度可持续发展（ESG）报告：提出"六防"核辐射防护手套的技术需求，与桂林理工大学联合 研发团队进行为期一年的科技攻关，对标先进企业核辐射防护手套产品的结构及性能，研发出具有化学 防护层、白色警示层、核辐射防护层和穿戴内层的多层核辐射防护手套的关键材料体系和成型工艺。 2、2025年3月3日官微：中红医疗亮相第12届京宠展。中红普林医疗用品股份有限公司（以下简称"中红 医疗"）携旗下健康防护、安全输注、创新孵化产品出席，其中迈德瑞纳宠物泵，备受瞩目。展会上， 中红医疗旗下迈德瑞纳 UniFusion SP50 Vet 及 UniFusion VP50 Vet 兽用输注泵备受关注，两款产品具备 IP34 防水设计和双 CPU 架构，能提供多种输液模式及微量模式最大流速设置，兼顾安全与多功能性。 兽医现场体验后表示，输注泵操作便捷，可切换电池或电源运行，能提供精准、安全、易用的输液方 案，适配多种场景 ...

5、公司属于国有企业。公司的最终控制人为厦门市人民政府国有资产监督管理委员会。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 1、2024年度可持续发展（ESG）报告：提出"六防"核辐射防护手套的技术需求，与桂林理工大学联合 研发团队进行为期一年的科技攻关，对标先进企业核辐射防护手套产品的结构及性能，研发出具有化学 防护层、白色警示层、核辐射防护层和穿戴内层的多层核辐射防护手套的关键材料体系和成型工艺。 2、2025年3月3日官微：中红医疗亮相第12届京宠展。中红普林医疗用品股份有限公司（以下简称"中红 医疗"）携旗下健康防护、安全输注、创新孵化产品出席，其中迈德瑞纳宠物泵，备受瞩目。展会上， 中红医疗旗下迈德瑞纳 UniFusion SP50 Vet 及 UniFusion VP50 Vet 兽用输注泵备受关注，两款产品具备 IP34 防水设计和双 CPU 架构，能提供多种输液模式及微量模式最大流速设置，兼顾安全与多功能性。 兽医现场体验后表示，输注泵操作便捷，可切换电池或电源运行，能提供精准、安全、易用的输液方 案，适配多种场景，是临床工作必备。 3、公司主营业务产品以 ...

来源：新浪证券-红岸工作室 12月12日，中红医疗跌3.21%，成交额1.24亿元，换手率2.29%，总市值58.15亿元。 异动分析 核污染防治+宠物经济+国企改革+医疗器械概念+人民币贬值受益 1、2024年度可持续发展（ESG）报告：提出"六防"核辐射防护手套的技术需求，与桂林理工大学联合 研发团队进行为期一年的科技攻关，对标先进企业核辐射防护手套产品的结构及性能，研发出具有化学 防护层、白色警示层、核辐射防护层和穿戴内层的多层核辐射防护手套的关键材料体系和成型工艺。 2、2025年3月3日官微：中红医疗亮相第12届京宠展。中红普林医疗用品股份有限公司（以下简称"中红 医疗"）携旗下健康防护、安全输注、创新孵化产品出席，其中迈德瑞纳宠物泵，备受瞩目。展会上， 中红医疗旗下迈德瑞纳 UniFusion SP50 Vet 及 UniFusion VP50 Vet 兽用输注泵备受关注，两款产品具备 IP34 防水设计和双 CPU 架构，能提供多种输液模式及微量模式最大流速设置，兼顾安全与多功能性。 兽医现场体验后表示，输注泵操作便捷，可切换电池或电源运行，能提供精准、安全、易用的输液方 案，适配多种场景，是临 ...

证券之星消息，12月11日，深港通医疗(港币)（983036）指数报收于4254.95点，跌1.68%，成交89.05亿 元，换手率1.12%。当日该指数成份股中，上涨的有5家，医脉通以4.26%的涨幅领涨，下跌的有52家， 中红医疗以6.1%的跌幅领跌。 深港通医疗(港币)（983036）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 资金流向方面，深港通医疗(港币)（983036）指数成份股当日主力资金净流出合计3.12亿元，游资资金 净流出合计2687.77万元，散户资金净流入合计3.39亿元。成份股资金流向详情见下表： ...

Core Viewpoint - Zhonghong Medical's stock price has declined, closing at 14.92 yuan with a drop of 3.24%, indicating a current state of underperformance since its IPO [1] Group 1: IPO and Initial Performance - Zhonghong Medical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on April 27, 2021, with an initial public offering of 41.67 million shares at a price of 48.59 yuan per share [1] - The stock reached a peak price of 159.80 yuan on its first trading day, marking the highest price since its listing [1] - Currently, the stock is in a state of decline, having fallen below its initial offering price [1] Group 2: Fundraising and Financials - The total amount raised from the IPO was 2.025 billion yuan, with a net amount of 1.896 billion yuan after expenses, exceeding the originally planned fundraising by 1.317 billion yuan [1] - The initial fundraising plan aimed to raise 580 million yuan for projects related to nitrile gloves and working capital [1] - The total issuance costs for the IPO were 128 million yuan, with underwriting fees accounting for 107 million yuan [1] Group 3: Dividend Distribution - In 2022, Zhonghong Medical announced a profit distribution plan, distributing 7.00 yuan in cash per 10 shares and increasing the total share capital by 9 million shares through capital reserve [2] - For 2021, the company distributed 30.00 yuan in cash per 10 shares and increased the total share capital by 13.33 million shares [2] - The 2024 profit distribution plan includes a cash dividend of 2.5 yuan per 10 shares and a capital reserve increase of 3.88 million shares, resulting in a total share capital of approximately 428.86 million shares [3]

Group 1 - Jinggong Technology signed a sales contract with Hubei Yuchuang worth 729 million yuan, accounting for 42.16% of the company's audited revenue for 2024 [1] - Heshun Electric is expected to win a bid for a State Grid procurement project worth 107 million yuan, representing 24.97% of the company's 2024 revenue [2] - Yongmaotai plans to invest approximately 400 million yuan in a new intelligent manufacturing project for magnesium-aluminum alloy materials [3] Group 2 - Longi Green Energy announced the termination of its plan to issue global depositary receipts abroad, stating it will not significantly impact its operations [4] - Bai Ao Intelligent is expected to win bids for projects totaling 27.5 million yuan [5] - Lian Biological is planning a change of control and asset purchase, leading to a temporary suspension of its stock [6] Group 3 - Bo Rui Communication intends to acquire 51% of Meijing Technology for 66.49 million yuan [7] - Huitai Medical plans to repurchase shares worth 200 to 250 million yuan for employee stock ownership plans [8] - Yifang Biological is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 4 - Jiuqiang Biological's shareholders signed an agreement for the transfer of 5% of the company's shares to China National Pharmaceutical Investment [11] - Songcheng Performing Arts plans to repurchase shares worth 100 to 200 million yuan for capital reduction [12] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project in Jiangxi Province [13] Group 5 - Xingfu Electronics plans to invest 480 million yuan in a new electronic-grade phosphoric acid project [14] - Jiaao Environmental Protection's stock will be subject to risk warnings due to an administrative penalty [15] - ST Nuotai received a drug registration certificate for a new injection [16] Group 6 - Haimo Technology plans to sell its controlling subsidiary, Xian Sitian Instrument, for 370 million yuan [17] - Jingce Electronics signed multiple sales contracts with a single customer totaling 433 million yuan [18] - Donghua Testing's controlling shareholder plans to reduce its stake by up to 1.99% [19][20] Group 7 - Xingqi Eye Medicine completed the first subject enrollment for a Phase II clinical trial of its eye drop product [21] - Kute Intelligent's controlling shareholder plans to reduce its stake by up to 2% [22] - Dongcheng Pharmaceutical's subsidiary received approval for a new specification of a heparin sodium injection [23] Group 8 - Zhaoyi Innovation is in the process of issuing H-shares and has received regulatory approval [24] - Aokang International's shareholder plans to reduce its stake by up to 3% [25] - Jiamei Packaging's controlling shareholder is planning a change of control, leading to a temporary stock suspension [26] Group 9 - ST Kevin's stock will have its risk warning lifted and will resume trading [27] - Zaiseng Technology's controlling shareholder plans to transfer 6.04% of the company's shares [28] - Lide New Energy's shareholder plans to reduce its stake by up to 1% [29] Group 10 - Srypu terminated its plan to acquire shares and will resume trading [30] - Longjiang Transportation's subsidiary plans to invest 2.679 billion yuan in a graphite mining project [31] - Haowei Group's controlling shareholder has not reduced its stake and has terminated the reduction plan [32] Group 11 - Huilun Crystal received an administrative penalty notice for information disclosure violations [33] - Haiguang Information terminated a major asset restructuring plan [34] - Zhongke Shuguang announced a cash dividend plan [35] Group 12 - Fushuo Technology's share purchase plan was approved by the Shenzhen Stock Exchange [36] - Dongbai Group's shareholder reduced its stake by 25.95 million shares [38]

（编辑 任世碧） 证券日报网讯 12月9日晚间，中红医疗发布公告称，公司于2025年12月8日召开第四届董事会第十五次 会议，审议通过了《关于公司及子公司2026年度向银行申请综合授信额度暨公司为子公司申请综合授信 额度提供担保的议案》，同意公司及控股子公司（包括2026年度新增的控股子公司）2026年度向相关银 行申请综合授信额度合计不超过50亿元，最终以各家银行实际审批的授信额度为准，其中以自有资产抵 质押等方式向上述金融机构申请授信额度总额不超过人民币10亿元，各抵质押主体可在总抵质押额度范 围内使用；并同意公司为控股子公司2026年度向金融机构申请的授信额度提供担保，担保额度总计不超 过25亿元，其中，为资产负债率70%（含）以上的控股子公司提供担保额度为不超过15亿元。 ...

转自：证券时报 人民财讯12月9日电，中红医疗(300981)12月9日公告，公司控股子公司科伦医械于近期参加江西省医用 耗材带量价格联动采购项目的投标工作。根据江西省医用耗材带量价格联动第一批带量联动品种拟中选 清单和采购需求量的公示结果显示，科伦医械产品一次性使用输液用肝素帽拟中选上述集中带量采购项 目。 ...

每经AI快讯，中红医疗（SZ 300981，收盘价：15.42元）12月9日晚间发布公告称，公司第四届第十五 次董事会会议于2025年12月8日以通讯方式召开。会议审议了《关于召开2025年第四次临时股东会的议 案》等文件。 2025年1至6月份，中红医疗的营业收入构成为：医疗器械行业占比100.0%。 截至发稿，中红医疗市值为66亿元。 每经头条（nbdtoutiao）——处方药变"瘾品"：国内首次报告普瑞巴林滥用致成瘾病例，网络平台暴 露"无病历可购药"漏洞，列管与否尚需科学考量 （记者 曾健辉） ...